Calypte Only Company with Full Menu of Tests.

Dr. George added, "Our EIA and Western Blot product lines are strong diagnostic tools with reliable customers that focus on a distinct opportunity in the HIV market, however going forward we see considerable near-term international growth opportunities in the rapid HIV and BED Incidence testing markets. Our decision to restructure is in keeping with our objective to distribute our resources towards our future; the rapid HIV testing platform and BED Incidence test."

"In the course of the coming quarters, Calypte intends to launch products in Africa, China, and other parts of Asia. We are conducting clinical trails to initiate the regulatory processes in these territories and plan to supply them through manufacturing arrangements in place in Thailand and in process in China."

Dr. George concluded, "I trust that all stockholders will understand that this plan is intended to extract the highest value from our technology and intellectual property. We believe our restructuring plan will allow us to more efficiently and economically focus on productivity and profitability."

Richard Brounstein, Executive Vice President and Chief Financial Officer said, "This initiative allows Calypte to focus its capital resources on the global launch of its rapid product line, the products that we believe represent a compelling opportunity. Calypte's administrative team plans to maintain the company's internal controls and corporate governance standards throughout the transition to a new staff in Portland and will ensure a seamless conversion throughout this process."

As part of the restructuring, Calypte has entered into a non-binding letter of intent to sell its urine EIA, serum Western Blot and urine Western Blot HIV in vitro diagnostic business. The terms of the sale are currently being negotiated and the Company expects to execute a definitive agreement during the current quarter.

About Calypte Biomedical:

Calypte Biomedical Corporation is a US-headquartered healthcare company focused on the development and commercialization of diagnostic testing products for the detection of sexually transmitted diseases. Calypte specializes in novel tests such as the HIV-1 BED Incidence EIA and is engaged in developing new diagnostic test products for the rapid detection of HIV and other sexually transmitted diseases, several of which do not require blood samples. Calypte believes that there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in lesser-developed countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2004 and its subsequent filings with the SEC.

    Company Contact:                      Investor Relations Contact:
    Richard George, President and CEO     Tim Clemensen,
    (925) 730-7200                        Rubenstein Investor Relations
    email:rgeorge@calypte.com             Phone: (212) 843-9337
                                          email:tclemensen@rubensteinir.com

SOURCE  Calypte Biomedical Corporation
   -0-                             04/21/2005
   /CONTACT:  Richard George, President and CEO of Calypte Biomedical
Corporation, +1-925-730-7200, rgeorge@calypte.com; Investor Relations - Tim
Clemensen of Rubenstein Investor Relations +1-212-843-9337,
tclemensen@rubensteinir.com, for Calypte Biomedical Corporation/
   /Web site:  www.calypte.com /
   (HIV)

CO:  Calypte Biomedical Corporation
ST:  California
IN:  BIO HEA MTC
SU:  RCN

DO
-- NYTH114 --
8613 04/21/2005 09:46 EDT www.prnewswire.com

Support/Resistance
Type Value Conf.
resist. 0.42 2
resist. 0.40 2
resist. 0.36 2
resist. 0.34 2
resist. 0.33 12
resist. 0.31 3
resist. 0.30 10
resist. 0.29 3
resist. 0.28 4
resist. 0.27 3
resist. 0.26 8
supp 0.25 3
supp 0.24 2
supp 0.23 10
supp 0.20 8


broker, für wie naiv hälst du die anderen mitgefangenen?

meinst du, die würden 66% des personals entlassen, wenn sie kurz vor großaufträgen stehen? .....aber klar, da kommt was großes auf euch zu.....






























DAS GROSSE ABLOSEN!!!!

gestern habe Ich versucht dir die Einzelheiten ins Ohr zu flüstern...

Ich wüßte nicht was an dem PR unverständlich sein sollte..

Ich gebe zu, ersten Reaktionen zu folge kann Ich sagen, daß es eine über Reaktion gegeben hat..

Dr. George berichtet ganz offen über die Tatsache, das Sie sich nur noch auf die Hochwertigen Produkte konzentrieren werden..

Vertraut mir, die haben die Ergebnisse und wissen, dass der Absatz kommt.
Die neue Technologie von Ani erspart auch so einiges, man ist effizienter...

Joelü zu dir züruck, du hast immer von grotten schlechten Zahlen berichtet, nicht wahr..

Die Alten Produkte laufen halt nicht, warum sollte man sich daran festhalten..
Es ist der richtige Weg, dass man jetzt die Resultate gesehen hat und das Nachfrage da ist, wo man sich jetzt vom überflüssigem trennt..

Die Zukunft ist in Rapid & Incidence Test's ...
Die Zukunft wovon Ich spreche ist in Naher Zeit...


Gruß

C.O